Ex Vivo Analysis of T-Cell Responses to Epstein-Barr Virus-Encoded Oncogene Latent Membrane Protein 1 Reveals Highly Conserved Epitope Sequences in Virus Isolates from Diverse Geographic Regions
- 1 July 2003
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 77 (13) , 7401-7410
- https://doi.org/10.1128/jvi.77.13.7401-7410.2003
Abstract
Epstein-Barr virus (EBV)-encoded oncogene latent membrane protein (LMP) 1, which is consistently expressed in multiple EBV-associated malignancies, has been proposed as a potential target antigen for any future vaccine designed to control these malignancies. However, the high degree of genetic variation in the LMP1 sequence has been considered a major impediment for its use as a potential immunotherapeutic target for the treatment of EBV-associated malignancies. In the present study, we have employed a highly efficient strategy, based on ex vivo functional assays, to conduct an extensive sequence-wide analysis of LMP1-specific T-cell responses in a large panel of healthy virus carriers of diverse ethnic origin and nasopharyngeal carcinoma patients. By comparing the frequencies of T cells specific for overlapping peptides spanning LMP1, we mapped a number of novel HLA class I- and class II-restricted LMP1 T-cell epitopes, including an epitope with dual HLA class I restriction. More importantly, extensive sequence analysis of LMP1 revealed that the majority of the T-cell epitopes were highly conserved in EBV isolates from Caucasian, Papua New Guinean, African, and Southeast Asian populations, while unique geographically constrained genetic variation was observed within one HLA A2 supertype-restricted epitope. These findings indicate that conserved LMP1 epitopes should be considered in designing epitope-based immunotherapeutic strategies against EBV-associated malignancies in different ethnic populations.Keywords
This publication has 24 references indexed in Scilit:
- Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinomaBlood, 2003
- Identification and prevalence of CD8+ T‐cell responses directed against Epstein‐Barr virus‐encoded latent membrane protein 1 and latent membrane protein 2International Journal of Cancer, 2002
- Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+T-Helper 1 ResponsesJournal of Virology, 2001
- Role of Cytotoxic T Lymphocytes in Epstein-Barr Virus-Associated DiseasesAnnual Review of Microbiology, 2000
- Epstein‐Barr virus in tumoursHistopathology, 1996
- Inhibition of antigen processing by the internal repeat region of the Epstein–Barr virus nuclear antigen-1Nature, 1995
- Sequence variation in the Epstein--Barr virus latent membrane protein 1Journal of General Virology, 1994
- Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.The Journal of Experimental Medicine, 1992
- Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.The Journal of Experimental Medicine, 1992
- Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformantsNature, 1988